Partially blocking blood vessels' energy source may stop cancer growth, blindness & other conditions
12/17/2013
Inhibiting the formation of new blood vessels is a common strategy for treating a range of conditions such as cancer, inflammatory diseases, and age-related macular degeneration. Unfortunately, drug inefficiency, resistance, and relapse have limited the success of this approach.
New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
12/17/2013
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Dasatinib is approved by the U.S.
Exercise can reduce drug-related joint pain in breast cancer patients, study shows
12/17/2013
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
'Breakthrough' may lead to new treatment for fatal childhood cancer
12/17/2013
Scientists have discovered an enzyme in the "developmental pathway" of patients with embryonal tumors within multilayers rosettes - an uncommon but deadly childhood brain cancer - which they say may lead to more effective treatment of the disease.
Skin cancer: new molecular targets identified
12/17/2013
Scientists have identified two molecular targets in some forms of skin cancer, which they say could lead to new treatment options for the disease. This is according to a study published in the the journal Clinical Cancer Research.The American Cancer Society state that skin cancer (melanoma) is the most common of all cancers.
First in-human trial of endoxifen shows promise as breast cancer treatment
12/17/2013
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found.
Younger, early breast cancer patients often undergo unnecessary staging, imaging procedures at time
12/17/2013
More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) - at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center.
Fruit fly studies help scientists swat aggressive relapsing leukemia
12/16/2013
Using genetic information initially uncovered in fruit fly studies, scientists have developed a unique therapeutic strategy that stops an aggressive and deadly form of leukemia in laboratory models of the disease.
Childhood cancer survivors suffer symptoms in adulthood
12/16/2013
More children are surviving cancer than ever before thanks to advances in treatment and technology. However, for about 70% of childhood cancer survivors, the effect of the disease and treatment 30 years later is sufficient to significantly affect their quality of life, according to a a new study led by the University of Florida (UF) in the US.
Cook Medical has initiated a clinical study in the U.S. to evaluate the removability of a new Evolution® Esophageal Fully Covered Stent. This is the first multicenter U.S. study to evaluate the possibility of removing a self-expanding metal stent after malignant and benign strictures have been treated. The stent design used in the study has been modified to accommodate retrieval.